Quidelortho Corp (QDEL) — SEC Filings
Quidelortho Corp (QDEL) — 49 SEC filings. Latest: 4 (Apr 22, 2026). Includes 21 8-K, 8 SC 13G/A, 7 SC 13D/A.
View Quidelortho Corp on SEC EDGAR
Overview
Quidelortho Corp (QDEL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 24, 2026: QuidelOrtho Corp filed an 8-K on March 24, 2026, reporting a significant change in its leadership structure under Item 5.02, specifically regarding the departure or appointment of certain officers and their compensation. This filing also includes a Regulation FD Disclosure under Item 7.01, indicatin
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 2 bearish, 47 neutral. The dominant filing sentiment for Quidelortho Corp is neutral.
Filing Type Overview
Quidelortho Corp (QDEL) has filed 1 4, 21 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 7 SC 13D/A, 1 8-K/A, 1 SC 13G, 1 10-K/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of QDEL's 36 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $699.9M |
| Net Income | -$733.0M |
| EPS | -$10.78 |
| Debt-to-Equity | 1.79 |
| Cash Position | $98.1M |
| Operating Margin | -100.6% |
| Total Assets | $5,675.1M |
| Total Debt | $2,659.0M |
Key Executives
- Brian J. Blaser
- Michael S. Iskra
- Douglas C. Bryant
- Douglas Bryant
Industry Context
QuidelOrtho operates in the diagnostics industry, a sector characterized by rapid technological advancements, regulatory scrutiny, and consolidation. The competitive landscape includes large, diversified healthcare companies and specialized diagnostic firms. Trends include the increasing demand for point-of-care testing, molecular diagnostics, and integrated diagnostic solutions, alongside pressure on pricing and reimbursement.
Top Tags
corporate-governance (8) · sec-filing (8) · ownership-change (6) · financial-reporting (5) · amendment (5) · executive-changes (3) · regulation-fd (3) · financial-condition (3) · results-of-operations (3) · 10-Q (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $733.0M | Increased significantly from $19.9M in Q3 2024, indicating severe financial deterioration. |
| Net Loss (YTD 2025) | $1,001.1M | Represents a substantial loss, though an improvement from $1,873.6M in YTD 2024 due to a larger prior-year impairment. |
| Goodwill Impairment Charge (Q3 2025) | $700.7M | A primary driver of the net loss, reflecting a significant write-down of asset values. |
| Total Revenues (Q3 2025) | $699.9M | Decreased from $727.1M in Q3 2024, showing a decline in top-line performance. |
| Total Revenues (YTD 2025) | $2,006.6M | Decreased from $2,075.1M in YTD 2024, indicating a year-over-year revenue decline. |
| Long-term Borrowings (Sept 2025) | $2,496.5M | Increased from $2,141.3M at Dec 2024, signaling higher financial leverage and debt burden. |
| Restructuring Charges (YTD 2025) | $234.6M | Significantly increased from $90.3M in YTD 2024, indicating ongoing and intensified cost-reduction efforts. |
| Total Assets (Sept 2025) | $5,675.1M | Decreased from $6,423.6M at Dec 2024, largely due to goodwill impairment. |
| Total Liabilities (Sept 2025) | $3,638.7M | Increased from $3,439.1M at Dec 2024, contributing to a weaker balance sheet. |
| Basic Loss Per Share (Q3 2025) | $10.78 | A significant increase from $0.30 in Q3 2024, reflecting the substantial net loss. |
| Net Loss | $10.1M | For Q2 2025, a swing from $15.3M net income in Q2 2024. |
| Revenue | $650.5M | For Q2 2025, a 4.2% decrease from $679.0M in Q2 2024. |
| Total Debt | $2.1B | As of June 29, 2025, indicating significant financial leverage. |
| Revenue Decrease | 4.2% | Year-over-year decline for the three months ended June 29, 2025. |
| Reporting Period End Date | 20250330 | Indicates the end of the fiscal quarter being reported. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Quidelortho Corp (QDEL)?
Quidelortho Corp has 49 recent SEC filings from Jan 2024 to Apr 2026, including 21 8-K, 8 SC 13G/A, 7 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of QDEL filings?
Across 49 filings, the sentiment breakdown is: 2 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Quidelortho Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Quidelortho Corp (QDEL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Quidelortho Corp?
Key financial highlights from Quidelortho Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for QDEL?
The investment thesis for QDEL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Quidelortho Corp?
Key executives identified across Quidelortho Corp's filings include Brian J. Blaser, Michael S. Iskra, Douglas C. Bryant, Douglas Bryant.
What are the main risk factors for Quidelortho Corp stock?
Of QDEL's 36 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Quidelortho Corp?
Forward guidance and predictions for Quidelortho Corp are extracted from SEC filings as they are enriched.